TLR4 Asp299Gly polymorphism associated with increased infection susceptibility (OR 2.05) and mortality (HR 1.78)Genetic variations linked to higher risk of severe infections

This systematic review and meta-analysis investigated the impact of specific TLR4 polymorphisms on clinical outcomes in individuals with Gram-negative infections. The study analyzed a total population of 9,196 individuals to determine how genetic variations, specifically Asp299Gly (rs4986790) and Thr399Ile (rs4986791), influenced infection risk and mortality rates. The analysis aimed to provide evidence on whether these polymorphisms serve as reliable biomarkers for clinical risk stratification in the context of Gram-negative bacterial infections.

The primary focus was the evaluation of the Asp299Gly variant. The meta-analysis reported that individuals carrying the Asp299Gly variant exhibited an increased susceptibility to infection, with a calculated odds ratio (OR) of 2.05 (95% CI: 1.72-2.45). Furthermore, this specific polymorphism was associated with significantly higher rates of infection-related mortality, yielding a hazard ratio (HR) of 1.78 (95% CI: 1.52-2.08). Regarding the Thr399Ile variant, the data indicated an increased risk of infection, although specific effect sizes and confidence intervals were not reported for this particular finding.

Secondary outcomes included the investigation of ethnogeographic variations in risk. The study addressed concerns regarding population diversity by stratifying results based on ethnogeographic ancestry. This stratification was necessary to address moderate heterogeneity observed in the initial data pool, where the I2 value was 48.3%. Following this stratification, the intra-subgroup I2 values were reduced to a range of 0-25%, thereby increasing the precision and reliability of the findings across different geographic groups.

Safety and tolerability data were not reported in the study as it focused on genetic associations rather than pharmacological interventions. No specific adverse events or discontinuation rates were documented. The analysis was designed to identify genetic markers for risk assessment rather than evaluating a therapeutic intervention, which limits the direct application of safety metrics to clinical treatment protocols.

These findings contribute to the understanding of how host genetics influence the severity and progression of Gram-negative infections. While previous research has established the role of TLR4 in innate immunity, this meta-analysis provides specific quantitative evidence linking the Asp299Gly variant to increased mortality. The results provide a foundation for more nuanced risk profiles in patients with known genetic predispositions.

Methodological limitations included the moderate heterogeneity (I2 = 48.3%) observed before ethnogeographic stratification. While this was mitigated by sub-group analysis, it highlights the importance of ancestry in interpreting genetic data. Additionally, as a meta-analysis of observational data, the study identifies associations rather than direct causation between the TLR4 polymorphisms and clinical outcomes. Clinically, these results provide a basis for genotype-stratified clinical trials of immunomodulatory agents. Identifying patients with the Asp299Gly variant may allow for more targeted interventions in high-risk individuals during Gram-negative infections. However, several questions remain unanswered regarding the specific mechanisms by which these polymorphisms influence mortality and whether they can be used as standalone predictors in acute clinical settings without additional biomarkers.